ME1 Stock Overview
Engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Melodiol Global Health Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.003 |
| 52 Week High | AU$0.26 |
| 52 Week Low | AU$0.002 |
| Beta | 2.56 |
| 1 Month Change | -25.00% |
| 3 Month Change | -78.57% |
| 1 Year Change | -98.93% |
| 3 Year Change | -99.91% |
| 5 Year Change | -99.97% |
| Change since IPO | -99.94% |
Recent News & Updates
Melodiol Global Health Limited (ASX:ME1) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny
May 01
Investors Give Melodiol Global Health Limited (ASX:ME1) Shares A 59% Hiding
Mar 02Shareholder Returns
| ME1 | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 20.0% | 5.0% | 0.7% |
| 1Y | -98.9% | 50.7% | 7.8% |
Return vs Industry: ME1 underperformed the Australian Pharmaceuticals industry which returned 50.6% over the past year.
Return vs Market: ME1 underperformed the Australian Market which returned 7.8% over the past year.
Price Volatility
| ME1 volatility | |
|---|---|
| ME1 Average Weekly Movement | 40.7% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: ME1's share price has been volatile over the past 3 months.
Volatility Over Time: ME1's weekly volatility has decreased from 53% to 41% over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Will Lay | melodiolglobalhealth.com |
Melodiol Global Health Limited engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific. It is involved in the development and commercialisation of nutraceutical products; and medical supplies business. The company was formerly known as Creso Pharma Limited and changed its name to Melodiol Global Health Limited in June 2023.
Melodiol Global Health Limited Fundamentals Summary
| ME1 fundamental statistics | |
|---|---|
| Market cap | AU$2.02m |
| Earnings (TTM) | -AU$35.52m |
| Revenue (TTM) | AU$18.92m |
0.1x
P/S Ratio-0.1x
P/E RatioIs ME1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ME1 income statement (TTM) | |
|---|---|
| Revenue | AU$18.92m |
| Cost of Revenue | AU$18.10m |
| Gross Profit | AU$817.00k |
| Other Expenses | AU$36.34m |
| Earnings | -AU$35.52m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.053 |
| Gross Margin | 4.32% |
| Net Profit Margin | -187.73% |
| Debt/Equity Ratio | -232.0% |
How did ME1 perform over the long term?
See historical performance and comparison